Stocks and Investing
Stocks and Investing
Mon, November 27, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Ashwani Verma Upgraded (TEVA) to Strong Buy and Increased Target to $13 on, Nov 27th, 2023
Ashwani Verma of UBS, Upgraded "Teva Pharmaceutical Industries Limited" (TEVA) to Strong Buy and Increased Target from $11 to $13 on, Nov 27th, 2023.
Ashwani has made no other calls on TEVA in the last 4 months.
There is 1 other peer that has a rating on TEVA. Out of the 1 peers that are also analyzing TEVA, 0 agree with Ashwani's Rating of Hold.
This is the rating of the analyst that currently disagrees with Ashwani
- Jason Gerberry of "B of A Securities" Maintained at Strong Buy with Increased Target to $13 on, Friday, September 8th, 2023
Contributing Sources